Korro Bio, Inc.(KRRO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Korro Bio, Inc. (KRRO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRRO at 14.1/100 on a 32-signal composite quality model, placing it at rank #2,871 of 2,962 stocks — the bottom half of the AI-ranked universe. KRRO scores in the top quartile across institutional flow (77.8). Areas of concern include revenue scale (0.8) and profitability (1.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Korro Bio, Inc. reports net income of $-18.9M, free cash flow of $-17.0M. Top institutional holders of KRRO by reported 13-F value include Lynx1 Capital Management, NEA Management Company, VR Adviser, based on the most recent SEC filings. KRRO trades on the Nasdaq exchange and files with the SEC under CIK 1703647. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Korro Bio, Inc. directly from SEC EDGAR.